NASDAQ: INABIn8bio Inc Stock
$1.05+0.05 (+5%)
Updated Apr 18, 2024
INAB Price
$1.05
Fair Value Price
$0.55
Market Cap
$45.45M
52 Week Low
$0.65
52 Week High
$3.95
P/E
-1.05x
P/B
1.82x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$30.01M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.35
Operating Cash Flow
-$23M
Beta
0.97
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
INAB Overview
IN8bio Incorporated is a biotech company developing gamma-delta T cell therapies for the treatment of cancers. Its pipeline includes INB-200, a genetically modified autologous gamma-delta T cell candidate in Phase I clinical trials for the treatment of glioblastoma and solid tumors, and INB-100, an allogeneic product candidate, in Phase I clinical trials to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. IN8bio was incorporated in 2016 and is headquartered in New York, NY.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INAB ($1.05) is overvalued by 91.34% relative to our estimate of its Fair Value price of $0.55 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INAB ($1.05) is not significantly undervalued (91.34%) relative to our estimate of its Fair Value price of $0.55 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INAB due diligence checks available for Premium users.
Be the first to know about important INAB news, forecast changes, insider trades & much more!
INAB News
Valuation
INAB fair value
Fair Value of INAB stock based on Discounted Cash Flow (DCF)
Price
$1.05
Fair Value
$0.55
Overvalued by
91.34%
INAB ($1.05) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INAB ($1.05) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.05x
Industry
15.68x
Market
41.33x
INAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.82x
Industry
5.76x
INAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INAB's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.6M
Profit Margin
0%
INAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$33.7M
Liabilities
$8.8M
Debt to equity
0.35
INAB's short-term assets ($24.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INAB's short-term assets ($24.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.9M
Investing
-$72.0k
Financing
$13.4M
INAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INAB vs Biotech Stocks
In8bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.